| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RNF11 |
| Uniprot No | Q9Y3C5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-154aa |
| 氨基酸序列 | GNCLKSPTSDDISLLHESQSDRASFGEGTEPDQEPPPPYQEQVPVPVYHPTPSQTRLATQLTEEEQIRIAQRIGLIQHLPKGVYDPGRDGSEKKIRECVICMMDFVYGDPIRFLPCMHIYHLDCIDDWLMRSFTCPSCMEPVDAALLSSYETN |
| 预测分子量 | 19.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RNF11重组蛋白的模拟参考文献示例(实际文献需通过数据库验证)：
1. **文献名称**: *RNF11 modulates TGF-β signaling by regulating Smurf2 degradation*
**作者**: Lixin Wan et al.
**摘要**: 研究利用重组RNF11蛋白，揭示其通过泛素化途径调控Smurf2的稳定性，进而影响TGF-β信号通路的活性。
2. **文献名称**: *RNF11 recombinant protein inhibits NF-κB activation in inflammatory models*
**作者**: Luca G. Guidotti et al.
**摘要**: 通过体外表达RNF11重组蛋白，证明其能竞争性结合TRAF6.抑制NF-κB通路活化，为炎症性疾病治疗提供潜在策略。
3. **文献名称**: *RNF11 interacts with ESCRT complexes via its PY motif: Role in EGFR degradation*
**作者**: James J. Hsieh et al.
**摘要**: 利用重组RNF11蛋白进行互作实验，发现其PY结构域介导与ESCRT复合物的结合，促进表皮生长因子受体(EGFR)的溶酶体降解。
4. **文献名称**: *Recombinant RNF11 as a therapeutic agent in breast cancer metastasis*
**作者**: Maria S. Soengas et al.
**摘要**: 动物实验表明，外源性重组RNF11蛋白可抑制乳腺癌细胞转移，机制涉及阻断泛素介导的Met受体信号传导。
**备注**：以上为模拟内容，实际文献需通过PubMed/Google Scholar以关键词“RNF11 recombinant protein”或“RNF11 ubiquitin ligase”检索。
**Background of RNF11 Recombinant Protein**
RNF11 (Ring Finger Protein 11) is an E3 ubiquitin ligase involved in regulating ubiquitination-dependent cellular processes, including protein degradation, signal transduction, and trafficking. It belongs to the RING finger protein family, characterized by a conserved RING domain that mediates interactions with E2 ubiquitin-conjugating enzymes. RNF11 plays a critical role in modulating pathways such as TGF-β, NF-κB, and EGFR signaling, often acting as a negative regulator to maintain cellular homeostasis. Its dysfunction has been linked to cancer, neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s), and immune disorders.
The recombinant RNF11 protein is engineered for in vitro studies to elucidate its molecular mechanisms. Produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), it retains functional domains, including the N-terminal RING finger, a central PY motif (for binding Nedd4-family E3 ligases), and a C-terminal transmembrane domain. Researchers use this purified protein to investigate its interactions with substrates (e.g., SMADs, IκBα) or partners (e.g., A20. Itch), as well as its enzymatic activity in ubiquitination assays.
RNF11’s recombinant form is also vital for drug discovery, enabling high-throughput screening for modulators of its E3 ligase activity or pathways it influences. In cancer research, it is studied for its dual roles—acting as a tumor suppressor in some contexts (e.g., inhibiting TGF-β-driven metastasis) or an oncogene in others (e.g., promoting EGFR stability). Additionally, its involvement in amyloid-β clearance and neuroinflammation highlights its therapeutic potential in neurodegenerative diseases. Overall, RNF11 recombinant protein serves as a key tool for dissecting its biological roles and developing targeted therapies.
×
